IGC Pharma Receives Patent From Canadian Intellectual Property Office Covering Composition Of IGC-AD1 Therapy For Agitation In Alzheimer
Benzinga Newsdesk 7 hours ago
NewsRegulationsGovernment
IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company advancing Alzheimer's disease therapeutics and Artificial Intelligence (AI) enabled healthcare
IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company advancing Alzheimer's disease therapeutics and Artificial Intelligence (AI) enabled healthcare technologies, today announced that the Canadian Intellectual Property Office granted Canadian Patent No. 3,095,729, "Method and Composition for Treating CNS Disorders".
The patent covers the composition of IGC-AD1, an investigational oral therapy for agitation in Alzheimer's.